Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC8EN0
|
|||
| Drug Name |
131I-labelled aCD45
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 3 | [1] | |
| Company |
Actinium Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte common antigen (PTPRC) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | B cell activation | |||
| JAK/STAT signaling pathway | ||||
| T cell activation | ||||
| Pathway Interaction Database | BCR signaling pathway | |||
| TCR signaling in naï | ||||
| TCR signaling in naï | ||||
| CXCR4-mediated signaling events | ||||
| Reactome | Phosphorylation of CD3 and TCR zeta chains | |||
| Other semaphorin interactions | ||||
| WikiPathways | Interferon type I signaling pathways | |||
| EPO Receptor Signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| TCR signaling | ||||
| Semaphorin interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health. | |||
| REF 2 | 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.